Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections
Related Questions
How will the FDA approval of ORLYNVAH™ affect ITRM's short‑term stock momentum and valuation multiples?
What is the competitive landscape for oral antibiotics targeting uncomplicated urinary tract infections, and how does ORLYNVAH™ differentiate itself in terms of efficacy, safety, and pricing?
What are the reimbursement prospects and potential sales volume for this first‑in‑class oral penem, and how might that influence ITRM's long‑term revenue growth and partnership opportunities?